vs
Side-by-side financial comparison of Webull Corp (BULL) and COLLEGIUM PHARMACEUTICAL, INC (COLL). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $131.5M, roughly 1.6× Webull Corp). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs -21.5%, a 29.8% gap on every dollar of revenue. On growth, Webull Corp posted the faster year-over-year revenue change (46.3% vs 12.9%). Webull Corp produced more free cash flow last quarter ($271.7M vs $122.4M).
Webull Corporation, often stylized as simply Webull, is a US-based financial services holding company headquartered in St. Petersburg, Florida. It provides an electronic trading platform of the same name.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
BULL vs COLL — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $131.5M | $205.4M |
| Net Profit | $-28.3M | $17.0M |
| Gross Margin | — | 62.5% |
| Operating Margin | -16.3% | 29.6% |
| Net Margin | -21.5% | 8.3% |
| Revenue YoY | 46.3% | 12.9% |
| Net Profit YoY | -144.3% | 35.3% |
| EPS (diluted) | — | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $205.4M | ||
| Q3 25 | — | $209.4M | ||
| Q2 25 | $131.5M | $188.0M | ||
| Q1 25 | — | $177.8M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $159.3M | ||
| Q2 24 | $89.9M | $145.3M | ||
| Q1 24 | — | $144.9M |
| Q4 25 | — | $17.0M | ||
| Q3 25 | — | $31.5M | ||
| Q2 25 | $-28.3M | $12.0M | ||
| Q1 25 | — | $2.4M | ||
| Q4 24 | — | $12.5M | ||
| Q3 24 | — | $9.3M | ||
| Q2 24 | $-11.6M | $19.6M | ||
| Q1 24 | — | $27.7M |
| Q4 25 | — | 62.5% | ||
| Q3 25 | — | 61.7% | ||
| Q2 25 | — | 57.7% | ||
| Q1 25 | — | 54.8% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 60.8% | ||
| Q2 24 | — | 62.5% | ||
| Q1 24 | — | 63.1% |
| Q4 25 | — | 29.6% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | -16.3% | 18.7% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 20.9% | ||
| Q3 24 | — | 21.9% | ||
| Q2 24 | -11.4% | 32.7% | ||
| Q1 24 | — | 34.1% |
| Q4 25 | — | 8.3% | ||
| Q3 25 | — | 15.0% | ||
| Q2 25 | -21.5% | 6.4% | ||
| Q1 25 | — | 1.4% | ||
| Q4 24 | — | 6.9% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | -12.9% | 13.5% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | — | $0.48 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | — | $0.34 | ||
| Q1 25 | — | $0.07 | ||
| Q4 24 | — | $0.36 | ||
| Q3 24 | — | $0.27 | ||
| Q2 24 | — | $0.52 | ||
| Q1 24 | — | $0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $476.7M | $386.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $751.6M | $301.7M |
| Total Assets | $2.6B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $386.7M | ||
| Q3 25 | — | $285.9M | ||
| Q2 25 | $476.7M | $222.2M | ||
| Q1 25 | — | $197.8M | ||
| Q4 24 | — | $162.8M | ||
| Q3 24 | — | $120.0M | ||
| Q2 24 | — | $271.6M | ||
| Q1 24 | — | $318.0M |
| Q4 25 | — | $301.7M | ||
| Q3 25 | — | $274.8M | ||
| Q2 25 | $751.6M | $232.2M | ||
| Q1 25 | — | $234.4M | ||
| Q4 24 | — | $228.8M | ||
| Q3 24 | — | $234.3M | ||
| Q2 24 | $-2.9B | $216.6M | ||
| Q1 24 | — | $222.2M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | $2.6B | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $272.1M | $123.0M |
| Free Cash FlowOCF − Capex | $271.7M | $122.4M |
| FCF MarginFCF / Revenue | 206.6% | 59.6% |
| Capex IntensityCapex / Revenue | 0.3% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 7.25× |
| TTM Free Cash FlowTrailing 4 quarters | — | $327.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $123.0M | ||
| Q3 25 | — | $78.4M | ||
| Q2 25 | $272.1M | $72.4M | ||
| Q1 25 | — | $55.4M | ||
| Q4 24 | — | $84.6M | ||
| Q3 24 | — | $-9.0M | ||
| Q2 24 | — | $67.4M | ||
| Q1 24 | — | $61.9M |
| Q4 25 | — | $122.4M | ||
| Q3 25 | — | $78.3M | ||
| Q2 25 | $271.7M | $72.4M | ||
| Q1 25 | — | $54.6M | ||
| Q4 24 | — | $84.1M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $67.1M | ||
| Q1 24 | — | $61.4M |
| Q4 25 | — | 59.6% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | 206.6% | 38.5% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 46.2% | ||
| Q3 24 | — | -5.8% | ||
| Q2 24 | — | 46.2% | ||
| Q1 24 | — | 42.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | 7.25× | ||
| Q3 25 | — | 2.49× | ||
| Q2 25 | — | 6.05× | ||
| Q1 25 | — | 22.92× | ||
| Q4 24 | — | 6.75× | ||
| Q3 24 | — | -0.96× | ||
| Q2 24 | — | 3.44× | ||
| Q1 24 | — | 2.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
